ClinicalTrials.gg
TerminatedNCT03853317Updated Aug 9, 2024Results posted

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

A Phase 2 interventional study of Avelumab and N-803 in Merkel Cell Carcinoma, sponsored by ImmunityBio, Inc.. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by ImmunityBio, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Not meeting recruitment goal

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 112 studies in Carcinoma, Merkel Cell with a site in United States — 27 open to participants now, 47 under way, 3 of them phase 3. Carcinoma, Merkel Cell · United States.

Enrollment
88th of 105
9 · median 40
Started
2020
with 8 others
Phase 2
35 of 112
7 open now
Registered
54th of 112
by date
Lead sponsor
3 of 112
ImmunityBio, Inc.

Among the 112 studies in Carcinoma, Merkel Cell with a site in United States, this one is the 88th largest by enrollment of the 105 interventional ones that give a count, is one of 9 that started in 2020, is one of 35 in phase 2, and was the 54th registered.

Carcinoma, Merkel Cell

150 studies on the registry are indexed under Carcinoma, Merkel Cell; 40 are open to participants now.

Browse Carcinoma, Merkel Cell studies →

Open to participants now

27 of the 112 studies in Carcinoma, Merkel Cell with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Carcinoma, Merkel Cell studies recruiting now, 27 (79%) set no upper age limit and none (0%) stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Carcinoma, Merkel Cell with a site in United States, or all of them as a file.
02

Study summary

Phase 2, single-arm study to evaluate combination therapy of avelumab, haNK and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients will receive treatment for a maximum of two years.

Read the detailed description

This is a phase II, single-arm study of combination therapy of avelumab, haNK, and N-803 in patients with Merkel Cell Carcinoma who have progressed on or after checkpoint inhibitor therapy as assessed by ORR. Patients must have progressed on or within six months of completing treatment with either avelumab or pembrolizumab. Patients will received treatment for a maximum of two years, with avelumab and haNK administered every two weeks, and N-803 administered every three weeks. Radiologic evaluation will occur every eight weeks during the first year of treatment, and every twelve weeks during the second year of treatment.

03

Conditions studied

  • Merkel Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years on day of signing .
  2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines.
  3. -confirmed MCC that has progressed during treatment or within 6 months after completing treatment with single-agent avelumab or pembrolizumab therapy, as per FDA indication.
  4. performance status of 0 to 2.
  5. Have at least 1 of ≥ 1.0 cm.
  6. Must have a recent FFPE tumor specimen following the conclusion of the most recent anticancer treatment and be willing to release the specimen for exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used.
  7. Must be willing to provide blood samples for exploratory analyses.
  8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
  9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  10. Agreement to practice effective for female subjects of and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non-sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and abstinence.

Exclusion criteria

Exclusion Criteria:

  1. Serious uncontrolled concomitant disease that would contraindicate the use of the drug used in this study or that would put the subject at high risk for treatment-related complications.
  2. Systemic disease (eg, lupus erythematosus, rheumatoid arthritis, [subjects with mild rheumatoid arthritis that aren't currently receiving treatment for their disease are eligible for enrollment], Addison's disease, or autoimmune disease associated with lymphoma).
  3. History of organ transplant requiring .
  4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  5. Inadequate organ function, evidenced by the following laboratory results:

    1. ANC \< 900 cells/mm3.
    2. count \< 75,000 cells/mm3
    3. Total greater than twice the (unless the subject has documented Gilbert's syndrome).
    4. (SGOT) or ALT (SGPT) > 2.5 × ULN (> 5 × ULN in subjects with liver ).
    5. ALP levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
  6. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of grade 2 or higher; or serious cardiac arrhythmia requiring medication.
  7. Dyspnea at rest due to complications of advanced or other disease requiring continuous oxygen therapy.
  8. Current chronic daily treatment (continuous for > 3 months) with systemic (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
  9. Known to any component of the study medication(s), including anaphylactic reaction to sulfur-containing medications.
  10. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
  11. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to the start of treatment on this study, except for testosterone-lowering therapy in men with prostate cancer.
  12. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  13. Concurrent participation in any interventional clinical trial.
  14. Pregnant and nursing women.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Treatment with avelumab, haNK™ and N-803

    The primary objective is to determine the efficacy of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy by objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    Biological: Avelumab · Biological: N-803 · Biological: haNK™

Interventions

  • BiologicalAvelumab

    For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).

    Also known as: (BAVENCIO® injection, for intravenous [IV] use)

  • BiologicalN-803

    Recombinant human super agonist interleukin-15 (IL-15) complex

    Also known as: also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]), ALT-803

  • BiologicalhaNK™

    haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).

    Also known as: NK-92 [CD16.158V, ER IL-2], (haNK™ for Infusion)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    The safety of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy

    Time frame: 30 days after last dose, approximately 1 year 7 months

  2. Objective Response Rate

    Percent of subjects with confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by RECIST v1.1

    Time frame: approximately 1 year 7 months

Secondary outcomes

  1. Overall Response Rate by iRECIST (Percent of Subjects With Confirmed Complete or Partial Overall Response)

    Percent of subjects with confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by iRECIST

    Time frame: Up to 2 years

  2. Progression Free Survival

    Defined as the time from the date of first treatment to disease progression or death by any cause, whichever occurs first by RECIST v1.1

    Time frame: Up to 2 years

  3. Progression Free Survival

    Defined as the time from the date of first treatment to disease progression or death by any cause, whichever occurs first by iRECIST

    Time frame: Up to 2 years

  4. Overall Survival

    Overall Survival defined as the time from the date of first treatment to death by any cause

    Time frame: Up to 2 years

  5. Disease-Specific Survival

    Disease-Specific Survival defined as the time from the date of first treatment to death resulting from MCC

    Time frame: Up to 2 years

  6. Disease Control Rate

    Percent of subjects with stable disease for \>= 8 weeks, or confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by RECIST v1.1

    Time frame: Up to 2 years

  7. Disease Control Rate

    Percent of subjects with stable disease for \>= 8 weeks, or confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by iRECIST

    Time frame: Up to 2 years

  8. FACT-M Total Score

    Quality of Life Measures as measured by the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) instrument's FACT-M Total Score. The FACT-M total score is a sum of the questions from its six subscales (a sum of 51 questions in total): Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns, and At the Site of Melanoma. All subscale questions use a 5-point Likert-type response score ranging from 0 = 'not at all' to 4 = 'very much'. The FACT-M Total score, therefore, ranges from 0 to 204. Negatively worded items are reverse scored prior to summing so that higher subscale and total scores indicate a better quality of life

    Time frame: Baseline, Week 13, and End of Treatment visit, up to 2 years

  9. Duration of Response by RECIST Version 1.1 and iRECIST

    Duration of Response is defined as the time from the date of first response (Investigator-assessed PR or CR) to the date of disease progression or death (any cause) whichever occurs first. Per RECIST and iRECIST: a complete response is the disappearance of all target lesions; a partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From time of CR or PR up to 2 years

07

Results

Posted Aug 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneTreatment With Avelumab, haNK™ and N-803
Started9
Completed0
Not completed9
Withdrew: Progressive disease5
Withdrew: Adverse event1
Withdrew: Death1
Withdrew: Other event2

Outcome measures

PrimaryNumber of Participants With Adverse Events

The safety of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy

Time frame:
30 days after last dose, approximately 1 year 7 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsTreatment With Avelumab, haNK™ and N-803
Number of Participants With Adverse Events9
PrimaryObjective Response Rate

Percent of subjects with confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by RECIST v1.1

Time frame:
approximately 1 year 7 months
Reported as:
Number · Percent of Subjects
Objective Response Rate
Percent of SubjectsTreatment With Avelumab, haNK™ and N-803
Objective Response Rate0 (0.0 to 33.6)
SecondaryOverall Response Rate by iRECIST (Percent of Subjects With Confirmed Complete or Partial Overall Response)

Percent of subjects with confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by iRECIST

Time frame:
Up to 2 years
Reported as:
Number · Percent of Subjects
Overall Response Rate by iRECIST (Percent of Subjects With Confirmed Complete or Partial Overall Response)
Percent of SubjectsTreatment With Avelumab, haNK™ and N-803
Overall Response Rate by iRECIST (Percent of Subjects With Confirmed Complete or Partial Overall Response)0 (0.00 to 33.6)
SecondaryProgression Free Survival

Defined as the time from the date of first treatment to disease progression or death by any cause, whichever occurs first by RECIST v1.1

Time frame:
Up to 2 years
Reported as:
Median · months
Progression Free Survival
monthsTreatment With Avelumab, haNK™ and N-803
Progression Free Survival1.9 (1.1 to 1.9)
SecondaryProgression Free Survival

Defined as the time from the date of first treatment to disease progression or death by any cause, whichever occurs first by iRECIST

Time frame:
Up to 2 years
Reported as:
Median · Months
Progression Free Survival
MonthsTreatment With Avelumab, haNK™ and N-803
Progression Free Survival1.9 (1.1 to NA)
SecondaryOverall Survival

Overall Survival defined as the time from the date of first treatment to death by any cause

Time frame:
Up to 2 years
Reported as:
Median · months
Overall Survival
monthsTreatment With Avelumab, haNK™ and N-803
Overall Survival5.6 (1.1 to NA)
SecondaryDisease-Specific Survival

Disease-Specific Survival defined as the time from the date of first treatment to death resulting from MCC

Time frame:
Up to 2 years
Reported as:
Median · months
Disease-Specific Survival
monthsTreatment With Avelumab, haNK™ and N-803
Disease-Specific SurvivalNA (1.9 to NA)
SecondaryDisease Control Rate

Percent of subjects with stable disease for \>= 8 weeks, or confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by RECIST v1.1

Time frame:
Up to 2 years
Reported as:
Number · Percent of Subjects
Disease Control Rate
Percent of SubjectsTreatment With Avelumab, haNK™ and N-803
Disease Control Rate0.00 (0.00 to 33.6)
SecondaryDisease Control Rate

Percent of subjects with stable disease for \>= 8 weeks, or confirmed complete Response (CR; disappearance of all target lesions) or partial response (PR; \>=30% decrease in the sum of the longest diameter of target lesions) by iRECIST

Time frame:
Up to 2 years
Reported as:
Number · Percent of Subjects
Disease Control Rate
Percent of SubjectsTreatment With Avelumab, haNK™ and N-803
Disease Control Rate0 (0.00 to 33.6)
SecondaryFACT-M Total Score

Quality of Life Measures as measured by the Functional Assessment of Cancer Therapy-Melanoma (FACT-M) instrument's FACT-M Total Score. The FACT-M total score is a sum of the questions from its six subscales (a sum of 51 questions in total): Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns, and At the Site of Melanoma. All subscale questions use a 5-point Likert-type response score ranging from 0 = 'not at all' to 4 = 'very much'. The FACT-M Total score, therefore, ranges from 0 to 204. Negatively worded items are reverse scored prior to summing so that higher subscale and total scores indicate a better quality of life

Time frame:
Baseline, Week 13, and End of Treatment visit, up to 2 years
Reported as:
Mean · Scores on a scale
FACT-M Total Score
Scores on a scaleTreatment With Avelumab, haNK™ and N-803
Baseline143.8 ± 26.55
Week 13144.5 ± 13.44
End of Treatment126.6 ± 31.55
SecondaryDuration of Response by RECIST Version 1.1 and iRECIST

Duration of Response is defined as the time from the date of first response (Investigator-assessed PR or CR) to the date of disease progression or death (any cause) whichever occurs first. Per RECIST and iRECIST: a complete response is the disappearance of all target lesions; a partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From time of CR or PR up to 2 years

No measurements were reported for this outcome.

Adverse events

Collected over 30 days after last dose, up to 2 years or until resolution or stabilization for nonserious grade 3 or 4 AEs and SAEs, whichever is longer.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment With Avelumab, haNK™ and N-8034/9 (44.4%)5/9 (55.6%)9/9 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment With Avelumab, haNK™ and N-803
AnaemiaBlood and lymphatic system disorders2/9
Oedema peripheralGeneral disorders1/9
Infusion related reactionInjury, poisoning and procedural complications1/9
HaematuriaRenal and urinary disorders1/9
Most frequent other events
Showing 10 of 51
Most frequent other events
EventTreatment With Avelumab, haNK™ and N-803
ChillsGeneral disorders5/9
pyrexiaGeneral disorders4/9
AnaemiaBlood and lymphatic system disorders4/9
HypoalbuminaemiaMetabolism and nutrition disorders4/9
Infusion related reactionInjury, poisoning and procedural complications3/9
fatigueGeneral disorders2/9
Injection site erythrmaGeneral disorders2/9
Injection site pruritusGeneral disorders2/9
Injection site reactionGeneral disorders2/9
Decreased appetiteMetabolism and nutrition disorders2/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment With Avelumab, haNK™ and N-803
Mean71.4 ± 8.06
Sex: Female, Male
Sex: Female, Male(Participants)Treatment With Avelumab, haNK™ and N-803
Female2
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment With Avelumab, haNK™ and N-803
Hispanic or Latino1
Not Hispanic or Latino7
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment With Avelumab, haNK™ and N-803
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race0
Unknown or Not Reported1
Histologically-confirmed metastatic MCC that has progressed during treatment or within 6 months
Histologically-confirmed metastatic MCC that has progressed during treatment or within 6 months(Participants)Treatment With Avelumab, haNK™ and N-803
Count of participants9
08

Study locations

5 sites
  • University of California San Francisco
    San Francisco, California 94143, United States
  • University of Miami, Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Miami Cancer Institute - Baptist Health
    Miami, Florida 33176, United States
  • Washington University School of Medicine in St. Louis
    Saint Louis, Missouri 63110, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Sep 2021, 19 months.

Results were first posted in Aug 2024, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2019
First posted
Feb 25, 2019
StartActual
Feb 19, 2020
Primary completionActual
Sep 29, 2021
CompletionActual
Sep 19, 2022
Results first posted
Aug 9, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03853317
Lead sponsor
ImmunityBio, Inc.
Responsible party
Sponsor
First posted
Feb 25, 2019
Start date
Feb 19, 2020
Primary completion
Sep 29, 2021
Completion
Sep 19, 2022
Results posted
Aug 9, 2024
Last update
Aug 9, 2024

Study contacts

Bobby Reddy, MD
study director · ImmunityBio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nogapendekin alfa inbakicept

Start the discussion